TOOKAD

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland.

Active ingredients

The drug TOOKAD contains one active pharmaceutical ingredient (API):

1	Padeliporfin UNII JQ72VD4XUL - PADELIPORFIN POTASSIUM
	Padeliporfin is retained within the vascular system. When activated with 753 nm wavelength laser light, padeliporfin triggers a cascade of pathophysiological events resulting in focal necrosis within a few days.
	Read more about Padeliporfin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TOOKAD Powder for solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XD07		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XD Sensitizers used in photodynamic/radiation therapy
Discover more medicines within L01XD07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1756807, 1756818
FR	Base de données publique des médicaments	65082422
IT	Agenzia del Farmaco	045774015, 045774027
LT	Valstybinė vaistų kontrolės tarnyba	1084469, 1084470
PL	Rejestru Produktów Leczniczych	100400647, 100400660